Feb 18, 2011, 05.01 PM IST

Transgene Biotek to raise $40m via GDR issue

Hyderabad-based biotechnology company Transgene Biotek plans to raise USD 40 million via global depositary receipt (GDR).

Transgene Biotek to raise $40m via GDR issue

Hyderabad-based biotechnology company Transgene Biotek plans to raise USD 40 million via global depositary receipt (GDR).

In an exclusive interview with CNBC-TV18's Ekta Batra and Reema Tendulkar, SS Marthi, Director of Transgene Biotek says, "The proposal is to raise USD 40 million via issuance of GDR. A part of this USD 40 million will be utilised for the present product line, which includes oncology drugs, active pharmaceutical ingredients (APIs), oral delivery platform of oral insulin, etc."

Going forward, the company is also looking at certain acquisitions, and, "the proceeds will be utilised for acquisitions as well," he adds.

The company is engaged in sales of medical diagnostic products and services.

Transgene Biote stock price

On April 17, 2014, Transgene Biotek closed at Rs 4.86, up Rs 0.13, or 2.75 percent. The 52-week high of the share was Rs 6.25 and the 52-week low was Rs 1.71.


The latest book value of the company is Rs 43.82 per share. At current value, the price-to-book value of the company was 0.11.

Set email alert for

ADS BY GOOGLE

Buy & sell politicians on Power Play
- the political stock exchange

Price Update

Rahul Gandhi

570.54 7.41 1.32%

340799

Bought today

361318

Sold today

0.81%

User holding

video of the day

Add cyclicals, banks on positive poll outcome: UBS

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.